explore -WSS

explore

author：comprehensive 2025-09-03 09:23:18 - browse：612

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Head of FDA's diagnostics center, who led through Covid, retires

hotspot

WSS

Mass General, Mayo Clinic look to monetize custom

Pumping milk in bathrooms at health conferences is common

Cardiologists urge adding sexual orientation, gender identity to health records

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

Faced with fears of OxyContin misuse, sales reps touted its safety

Mass General, Mayo Clinic look to monetize custom

hotspot

explore

focus

BioMarin wins approval for gene therapy to treat hemophilia A

What causes osteoarthritis? Researchers study link to brain protein

Dobbs anniversary: the lost opportunity of abortion as health care

Novo acquires Inversago for up to $1 billion

Moonlake's readout produced a cash windfall. Risks remain

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

Drug repurposing or repositioning? The language matters

Novo acquires Inversago for up to $1 billion

Activists slam private health insurers over coverage restrictions

Some of the ways extreme heat will change life as we know it

hotspot

A pediatrician calls for Congress to pass the child tax credit deal

FDA sets aggressive timeline for overhauling inspection procedures

Where are patients getting their prescriptions for GLP

Printout prescription drug information shouldn’t go digital

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

HPV vaccine, cervical cancer study delivers historic results

leisure time

hotspot

entertainment

hotspot